Csaba, Noemi StefaniaGrandjean, CyrillePrasanna, Maruthi2020-12-172020-12-172020http://hdl.handle.net/10347/24042The currently available pneumococcal vaccines are not effective in complete prevention of pneumococcal infections. To develop a better vaccine, firstly, we produced a glycoconjugate antigen based on common pneumococcal vaccine. Based on the positive immune responses generated by the glycoconjugate antigen in the mice, we further envisage that their combination with the nanotechnologies would generate a vaccine with enhanced potential. In this line, we utilized chitosan nanoparticles to encapsulate the glycoconjugate. Finally, the developed nanovaccines generated an enhanced immune response against both the protein and polysaccharide components when compared to the naked glycoconjugate.engAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/GlycoconjugateChitosanNanoparticlesVaccinesPsaAPneumoniaMaterias::Investigación::32 Ciencias médicas::3209 Farmacología::320908 Preparación de medicamentosMaterias::Investigación::32 Ciencias médicas::3209 Farmacología::320903 Evaluación de medicamentosMaterias::Investigación::24 Ciencias de la vida::2412 Inmunología::241210 Vacunasdoctoral thesisopen access